What changed in Dexcom, Inc.'s latest annual report
In the year ended 31 Dec 2025, Dexcom, Inc.'s revenue rose 15.6% to USD 4.66bn, from USD 4.03bn; net income rose 45.1% to USD 836.30m, from USD 576.20m; cash and cash equivalents rose 51.4% to USD 917.70m, from USD 606.10m.
Year ended 31 Dec 2025. Source: 10-K filed 12 Feb 2026, read it on SEC EDGAR.
USD 4.03bn to USD 4.66bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 4.03bn | 4.66bn | Up 15.6% |
| Net income | 576.20m | 836.30m | Up 45.1% |
| Total assets | 6.48bn | 6.34bn | Down 2.2% |
| Total liabilities | 4.38bn | 3.59bn | Down 18% |
| Cash and cash equivalents | 606.10m | 917.70m | Up 51.4% |
| Shareholders' equity | 2.10bn | 2.75bn | Up 30.6% |
Questions people ask
Did Dexcom, Inc.'s revenue grow last year?
Revenue grew 15.6%, from USD 4.03bn to USD 4.66bn in the year ended 31 Dec 2025.
Is Dexcom, Inc. profitable?
Yes. Net income was USD 836.30m in the year ended 31 Dec 2025. The year before: USD 576.20m.
How much cash and debt does Dexcom, Inc. have?
At its latest year end (31 Dec 2025), Dexcom, Inc. reported cash and cash equivalents of USD 917.70m.
Where do these numbers come from?
From Dexcom, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Dexcom, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%
- Solventum CorporationNet income up 224.8%